PREDICTIVE VALUE OF IL28B GENE POLYMORPHISM COMBINED WITH PRE-TREATMENT SERUM IP-10 QUANTIFICATION FOR RESPONSE TO PEGINTERFERON AND RIBAVIRIN ENHANCED IN COMPARISON WITH ANY OF THESE BIOMARKERS ALONE

• Main Authors: MICHAEL W FRIED, JEROEN AERSSENS, GREGORY CHARLES FANNING
• Format: Patent
• Language: English; Japanese
• Published: 04.08.2016
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS OR TEST PAPERS THEREFOR; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL ORENZYMOLOGICAL PROCESSES; ENZYMOLOGY; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES; MEASURING; MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEICACIDS OR MICROORGANISMS; METALLURGY; MICROBIOLOGY; MUTATION OR GENETIC ENGINEERING; PHYSICS; PROCESSES OF PREPARING SUCH COMPOSITIONS; SPIRITS; TESTING; VINEGAR; WINE

PROBLEM TO BE SOLVED: To provide means for more accurately predicting the outcome of a sustained virological response (SVR) or non-response to peginterferon and ribavirin for each patient infected with HCV.SOLUTION: Disclosed is a method of combining IL28B genotype determination with pre-treatment serum level measurement of IP-10 to more accurately predict the outcome of a sustained virological response (SVR) or non-response to peginterferon and ribavirin for individual patients infected with HCV.SELECTED DRAWING: None 【課題】ＨＣＶに感染した個々の患者に関するペグインターフェロン及びリバビリンへの持続性ウイルス学的反応（ＳＶＲ）又は無−反応の結果をより正確に予測するための手段の提供。【解決手段】ＨＣＶに感染した個々の患者に関するペグインターフェロン及びリバビリンへの持続性ウイルス学的反応（ＳＶＲ）又は無−反応の結果をより正確に予測するために、ＩＬ２８Ｂ遺伝子型決定をＩＰ−１０の処置前血清レベル測定値と組み合わせる方法。【選択図】なし